The antitumor efficacy of the EpCAM peptide-pulsed, DC-induced CTLs in HepG2 tumor-bearing mice. Yoo Jin Choi Seong-Joon Park You-Soo Park Hee Sung Park Kwang Mo Yang Kyu Heo 10.1371/journal.pone.0190638.g005 https://plos.figshare.com/articles/figure/The_antitumor_efficacy_of_the_EpCAM_peptide-pulsed_DC-induced_CTLs_in_HepG2_tumor-bearing_mice_/5755062 <p>(A) The experimental setup and showing the injection schedule for the tumor-associated antigen-pulsed, DC-induced CTLs. (B) Inhibition of tumor growth analysis. Tumor-bearing BALB/c nude mice were treated with intravenous injections of Pep-CTLs (EpCAM peptide stimulated DC-CTLs), TL-CTLs (HepG2 cell lysate stimulated DC-CTLs), DC-CTLs and T cells on days 10 and 17 after tumor implantation. (C) EpCAM<sup>+</sup> HepG2-specific cytotoxicity. Lymphocytes were isolated from the Pep-CTL-, TL-CTL-, DC-CTL- or T cell-treated mice on day 14 post-inoculation. (D) Immunohistochemistry with anti-EpCAM antibodies in HepG2 tumor tissue. Tumor regions of a section from a tumor isolated on day 24 after tumor implantation. Original magnification, 200×. The data are expressed as the mean±SD, and significant differences between the treated groups were detected using ANOVA followed by the Dunnett’s test. <sup>#</sup><i>P</i><0.05 compared with the DC-CTLs, and * <i>p</i><0.05 compared with the TL-CTLs.</p> 2018-01-03 18:38:33 peptide-T 2 binding assay EpCAM peptides anti-tumor immunity HLA-A 2 molecules antigen CTL CSC marker MHC cytotoxic T lymphocytes HCC CD 44 T cell stimulation breast cancer EpCAM peptide-primed dendritic cell vaccination TAA hepatocellular carcinoma cells Cancer stem-like cells DC